This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

MLex Comment: Merck, Schering-Plough EC review likely to focus on animal health and asthma markets

By Dafydd Nelson ( March 27, 2009, 09:11 GMT | Comment) -- A first look at Merck’s acquisition of Schering-Plough reveals that Merck may have to divest some animal health offerings, in the context of an eventual European Commission review of the transaction. Scrutiny is also likely to fall on the companies’ asthma products. But these concerns are unlikely to unduly complicate a deal that could be cleared in a Phase I review with remedies.European antitrust regulators will again be tested by the pharmaceutical sector’s latest ‘mega-merger’. Merck’s 41 billion dollars acquisition of Schering-Plough comes just weeks after Pfizer announced its purchase of rival company Wyeth....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login